The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular ...
First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after ...
Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...
Two commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth with strong China market presenceNext-generation ...
Maryland Gov. Wes Moore said he plans to introduce a balanced budget that prioritizes education and safety in the final ...
Adults with type 1 diabetes who used a GLP-1 receptor agonist or other incretin-based drug had lower risk for all-cause ...
TROPION-Lung17 will enroll approximately 400 patients across global sites. Participants are randomized 1:1 to receive either ...
(Alliance News) - Hutchmed China Ltd on Wednesday said the results from its SACHI phase-three lung cancer trial have been published in medical journal the Lancet.
Novo Nordisk's FDA-approved Wegovy pill marks a new era in obesity treatment, expanding access to GLP-1 therapy through ...
The first two days of the J.P. Morgan Healthcare Conference are in the books, and attendees are now pushing through to finish ...
Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its ...
TherML™ integrates CombinAbleAI’s advanced, next generation biologics expertise with insitro’s existing small molecule and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback